Eli Lilly and Company recently presented at Morgan Stanley’s Global Healthcare Conference, where executive vice president Ilya Yuffa outlined efforts to expand access to its obesity medicines, including Zepbound and Foundayo, and highlighted broader international growth initiatives. This focus on widening obesity treatment access through consumer advertising, Medicare Bridge support, and global reach underlines how central these therapies have become to Lilly’s long-term business mix. We’ll...

Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.99% move from its prior day

Eli Lilly says Foundayo captured 30%+ of new U.S. oral weight-loss patients, challenging Novo’s Wegovy pill lead. Read more here.

Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing convenience, according to Ilya Yuffa, the company’s executive vice president and president of Lilly USA and G

Eli Lilly and Company completed its previously announced acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company.

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

During the Mad Money episode aired on September 8, Jim Cramer highlighted Eli Lilly and Company (NYSE:LLY) as a top-tier compounder driven by its booming GLP-1 weight-loss and diabetes treatments. Comparing the pharmaceutical leader to Indianapolis Colts running back Jonathan Taylor, Cramer said: Beyond that, I’ve got a couple more running backs. Eli Lilly’s become […]

Eli Lilly finalized its acquisition of AtaiBeckley on September 11, 2026, paying $6.75 per share in cash for an immediate equity value of about $2.8…